Kyverna Therapeutics, Inc. Common Stock Asset Resilience Ratio
Kyverna Therapeutics, Inc. Common Stock asset resilience ratio. Kyverna Therapeutics, Inc. Common Stock (KYTX) has an Asset Resilience Ratio of 79.47% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read KYTX current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Kyverna Therapeutics, Inc. Common Stock (2021–2025)
Asset resilience ratio of Kyverna Therapeutics, Inc. Common Stock from 2021 to 2025. This chart shows how Kyverna Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. See KYTX FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Kyverna Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Kyverna Therapeutics, Inc. Common Stock's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $204.25 Million | 79.47% |
| Total Liquid Assets | $204.25 Million | 79.47% |
Asset Resilience Insights
- Very High Liquidity: Kyverna Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 79.47% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Kyverna Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Kyverna Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.57% |
|
Eupraxia Pharmaceuticals Inc
TO:EPRX |
Biotechnology | 25.13% |
|
Cabio Biotech Wuhan Co Ltd
SHG:688089 |
Biotechnology | 3.60% |
Kyverna Therapeutics, Inc. Common Stock Asset Resilience Ratio by Year (2021–2025)
Kyverna Therapeutics, Inc. Common Stock asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for Kyverna Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 52.81% | $155.16 Million | $293.83 Million | -9.35pp |
| 2024-12-31 | 62.16% | $189.36 Million | $304.64 Million | +31.71pp |
| 2023-12-31 | 30.45% | $22.90 Million | $75.19 Million | +10.15pp |
| 2022-12-31 | 20.30% | $13.59 Million | $66.92 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $85.49 Million | -- |
About Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product ca… Read more